In comparison to IL2-RA induction therapy, R-ATG is associated with increased risk of development of PTLD (odds ratio = 1.83, confidence interval ranges from 1.001 to 3.34, p = .048). The gene discussed is IL2; the disease is post-transplant lymphoproliferative disease.